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Abstract
OBJECTIVES: Atrial fibrillation (AF) reduces survival and quality of life (QoL). It can be treated at the time of major cardiac sur-
gery using ablation procedures ranging from simple pulmonary vein isolation to a full maze procedure. The aim of this study is to
evaluate the impact of adjunct AF surgery as currently performed on sinus rhythm (SR) restoration, survival, QoL and cost-
effectiveness.
METHODS: In a multicentre, Phase III, pragmatic, double-blinded, parallel-armed randomized controlled trial, 352 cardiac surgery pa-
tients with >3 months of documented AF were randomized to surgery with or without adjunct maze or similar AF ablation between 2009
and 2014. Primary outcomes were SR restoration at 1 year and quality-adjusted life years at 2 years. Secondary outcomes included SR at
2 years, overall and stroke-free survival, medication, QoL, cost-effectiveness and safety.
RESULTS: More ablation patients were in SR at 1 year [odds ratio (OR) 2.06, 95% confidence interval (CI) 1.20–3.54; P = 0.009]. At 2 years,
the OR increased to 3.24 (95% CI 1.76–5.96). Quality-adjusted life years were similar at 2 years (ablation - control -0.025, P = 0.6319).
Significantly fewer ablation patients were anticoagulated from 6 months postoperatively. Stroke rates were 5.7% (ablation) and 9.1% (con-
trol) (P = 0.3083). There was no significant difference in stroke-free survival [hazard ratio (HR) = 0.99, 95% CI 0.64–1.53; P = 0.949] nor in
serious adverse events, operative or overall survival, cardioversion, pacemaker implantation, New York Heart Association, EQ-5D-3L and
SF-36. The mean additional ablation cost per patient was £3533 (95% CI £1321–£5746). Cost-effectiveness was not demonstrated at
2 years.
CONCLUSIONS: Adjunct AF surgery is safe and increases SR restoration and costs but not survival or QoL up to 2 years. A continued
follow-up will provide information on these outcomes in the longer term.
Study registration: ISRCTN82731440 (project number 07/01/34).
Keywords: Randomized trial • Atrial fibrillation • Ablation • Maze procedure • Cardiac surgery • Cost-effectiveness
†Trial institutions (all in the UK): Papworth Hospital, Cambridge; Glenfield Hospital, Leicester; University of Leeds, Leeds; Brunel University, London; Derriford
Hospital, Plymouth; Northern General Hospital, Sheffield; London School of Hygiene and Tropical Medicine, London; Freeman Hospital, Newcastle; Wythenshawe
Hospital, Manchester; Royal Sussex County Hospital, Brighton; University Hospital, Coventry; Royal Brompton Hospital, London; Guy’s & St Thomas’s Hospital,
London; Victoria Hospital, Blackpool.
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INTRODUCTION
The prevalence of atrial fibrillation (AF) is 1–2% in the developed
world, rising with age and comorbidity [1]. UK prevalence is 7.2%
after age 65 and 10.3% after 75 [2] and will rise further with life ex-
pectancy. Symptoms include palpitations, chest pain, dizziness and
breathlessness. Loss of atrial contractility increases the risk of
thromboembolic stroke [3]. Anticoagulation reduces stroke but in-
creases bleeding risk [4]. Atrial function loss may cause or exacer-
bate heart failure. AF has substantial impact on care and resources.
AF pathophysiology is now better understood: triggered most
often by pulmonary vein foci, it is maintained through macro-
re-entry circuits of 4–5 cm in diameter [5], leading to the devel-
opment of the Cox-maze procedure in the 1980s [6]: through
median sternotomy with cardiopulmonary bypass, the atria are
cut and sutured to achieve pulmonary vein electrical isolation
and interruption of macro-re-entry circuits. Despite success in
restoring sinus rhythm (SR) [7], this challenging procedure is usu-
ally reserved for severely symptomatic patients, and the world-
wide number of cut-and-sew Cox-maze procedures is extremely
small in relation to AF prevalence.
Some or all the Cox-maze procedure blocks can be achieved by
energy sources to ablate atrial tissue: easier, quicker and safer but
expensive. Many cardiac surgery patients have AF. Whether they
should routinely have adjunct AF surgery is unknown. Current
practice varies widely between surgeons and hospitals. AF surgery
increases SR restoration rate and decreases antiarrhythmic medica-
tion use [8–10]. However, the impact on patient-relevant out-
comes, such as survival and health-related QoL (HRQoL), is
uncertain. Cost-effectiveness analyses have mixed results [11, 12],
are limited by the lack of HRQoL evidence in the short term and
medium term (1–5 years) and economic models are not robust.
The Amaze trial aimed to evaluate clinical and HRQoL outcomes
and cost-effectiveness of this technology by comparing AF surgery
as an adjunct to cardiac surgery with cardiac surgery alone.
METHODS
The Amaze trial was a Phase III, pragmatic, multicentre, double-
blinded, parallel-armed, randomized controlled superiority trial
(RCT) in 11 cardiac surgical centres. Thirty surgeons participated
with at least 2 years of experience in AF surgery.
Patient recruitment
Consecutive cardiac surgery patients with a history of AF were
screened. Inclusion criteria were age >_18 years, elective or urgent
cardiac surgery (coronary, valve, combined and other surgery requir-
ing cardiopulmonary bypass), documented history (>3 months) of AF
(non-paroxysmal or paroxysmal). Exclusion criteria were previous
cardiac operations, emergency or salvage operations, off-pump sur-
gery, unavailability for follow-up and inability to consent..
Randomization
Group allocation (1:1) was computer-generated by the trial statis-
tician, using permuted block randomization (Sizes 6 and 8), strati-
fied by surgeon and planned procedure. Randomization to
planned cardiac surgery (control arm) or planned cardiac surgery
with additional maze or similar ablation procedure (ablation
arm) was performed on the operation day.
Blinding
The operating room staff could not be blinded to treatment alloca-
tion. After surgery, procedure details were kept in sealed envelopes in
patient notes and only retrieved in a clinical emergency. Patients, car-
diologists assessing electrocardiogram (ECG) results and researchers
collecting HRQoL outcomes were unaware of treatment arm.
Clinical management
Local protocols were followed for operative and perioperative man-
agement and were identical in both arms. AF surgery in the interven-
tion arm was conducted by an experienced surgeon. The Amaze
trial was a pragmatic trial evaluating AF ablation as currently per-
formed, so ablation methods and lesion sets were left to the surgeon:
any device in clinical use was permitted, including bipolar and uni-
polar radiofrequency, ‘cut-and-sew’, cautery, cryotherapy, ultrasound,
laser and microwave. Lesion sets and devices used were recorded.
Outcomes
SR restoration at 1 year after surgery and quality-adjusted life years
(QALYs) over 2 years were joint primary outcomes. SR restoration
required the absence of any AF on 4-day continuous ECG analysed
by cardiologists unaware of patient identity or treatment arm. QALYs
over 2 years were estimated from serial utility measurements from
the UK population valuation of the EuroQoL EQ-5D-3l at randomiza-
tion, discharge, 6 weeks, 6, 12 and 24 months postoperatively.
Secondary outcomes were 2-year SR restoration, overall survival,
stroke-free survival, hospital admission for haemorrhage, antiarrhyth-
mic and anticoagulant drug usage, New York Heart Association
(NYHA), HRQoL (SF-36), resource use and cost-effectiveness at
2 years. Prespecified subgroup analyses explored outcome differences
using AF type, surgeons and cardiac procedure. Outcomes of lesion
sets and method of ablation were compared within the trial arm.
Sample size
AF surgery was considered effective if there was a significant im-
pact on either 1-year SR rates or 2-year quality-adjusted survival.
The target (200 patients/arm) was based on detecting a 15% differ-
ence in the proportion of patients in SR at 1 year (45% vs 30%) or
1 additional month of quality-adjusted life [0.083 QALYs, standard
deviation (SD) 0.3] over 2 years, with approximately 80% power,
2-sided significance of 5% and up to 15% death/loss to follow-up.
Because of slower-than-expected accrual, recruitment stopped at
352 (88% target) patients, reducing the power to detect the pro-
posed treatment effects to more than 70% for primary outcomes.
To guard against overinterpretation of hypothesis tests due to mul-
tiple testing, we recommend that P-values between 0.025 and 0.05
are considered of borderline significance.
Statistical analysis
Primary outcome analysis was performed by intention to treat.
SR restoration was analysed by logistic regression, including sur-
geon (random intercepts), baseline rhythm and planned proced-
ure (fixed effects). For QALYs, linear regression, including surgeon
(random intercepts), baseline utility and treatment arm (fixed ef-
fects), was fitted to utilities post-treatment. For survivors with
missing EuroQoL measurements, multiple imputation was used,
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and QALY difference confidence interval (CI) was estimated using
non-parametric bootstrapping. No primary outcome discounting
was applied, and no adjustment was made for multiplicity.
Sensitivity to assumptions surrounding missing data mechanisms
were explored with no changes in results. For primary outcomes,
prespecified subgroup effects were explored by including inter-
action terms, except for surgeon where a random effect was applied
to the treatment coefficient. Lesion set effects were assessed in the
ablation arm against a reference category. Adverse events by inter-
vention were categorized by severity and relationship to procedure.
Survival and stroke-free survival were analysed using the Kaplan–
Meier and Cox regression. The SF-36 score analysis used linear re-
gression, including time point, treatment arm, time-by-treatment
arm interaction and baseline scores (fixed effects), with random
intercepts for patients. Antiarrhythmic and anticoagulant use was
tabulated by time and category and analysed by logistic regression.
Economic analysis
Resource use data from primary admission (time in theatre, in-
tensive care and wards, hospital transfer, diagnostics and antiar-
rhythmic, antiplatelet, anticoagulant and cardiac drugs) were
Figure 1: Patient flow through the Amaze trial. ECG: electrocardiogram; PAPVD: partial anomalous pulmonary venous drainage; QALY: quality-adjusted life year; SR:
sinus rhythm.
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extracted from records, supplemented by patient-reported post-
discharge health service use. Resources were valued using na-
tional estimates (https://www.evidence.nhs.uk/formulary/bnf/cur
rent; http://www.drugtariff.nhsbsa.nhs.uk/; http://www.pssru.ac.
uk/project-pages/unit-costs/2015/; https://www.gov.uk/govern
ment/publications/nhs-reference-costs-2014-to-2015/) literature
(blood pressure monitoring and radiology) [13, 14] and data
from the Papworth Hospital (operating room and device cost).
High-intensity focussed ultrasound costed £3000, and other
methods costed £1250. Type missingness was examined and
replaced with mean or imputed values. Missing resource and util-
ity data were imputed jointly using chained equations with pre-
dictive mean matching. Costs and QALYs were discounted at
3.5% in year 2. Incremental cost-effectiveness ratios relied on
seemingly unrelated regression, controlling for baseline differ-
ences in age, gender, EQ-5D-3l, AF and (for QALYs) the primary
surgery. Probabilistic sensitivity analysis used bootstrapping.
Cost-effectiveness planes, acceptability curve and incremental
net monetary benefit were estimated. Deterministic sensitivity
analysis explored the impact of using SF-6D QALYs, complete
case analysis, truncating costs and discharge QALYs, excluding
outliers and alternative imputation strategies.
RESULTS
Between February 2009 and March 2014, 1013 patients were
screened by 30 surgeons in 11 centres: 352 were randomized
(176 each) to control or ablation arms. Exclusions applied to
366 patients (Supplementary Material, Table S1). Thirteen
(3.7%) patients did not receive allocated treatment: 11 (6.3%)
patients from the ablation arm due to technical issues and 2
(1.1%) from the control arm due to surgeon-perceived benefit
after randomization (Fig. 1). One-year SR status was available
Table 1: Baseline characteristics of patients randomized in
the Amaze trial
Ablation Control Total
(n = 176) (n = 176) (n = 352)
Age (years)
Mean (SD) 72.3 (7.53) 71.4 (7.81) 71.9 (7.67)
Range 50.0–86.0 48.0–89.0 48.0–89.0
Sex
Male, n (%) 112 (63.6) 120 (68.2) 232 (65.9)
Female, n (%) 64 (36.4) 56 (31.8) 120 (34.1)
Body mass index (kg/m2)
Mean (SD) 28.1 (5.27) 27.6 (4.62) 27.9 (4.96)
Range 17.4–46.0 17.9–42.8 17.4–46.0
Logistic EuroSCORE (%)
Mean (SD) 6.94 (5.489) 6.64 (4.869) 6.79 (5.184)
Range 0.88–30.41 1.40–23.85 0.88–30.41
CCS class, n (%)
0 125 (71.0) 133 (75.6) 258 (73.3)
1 13 (7.4) 17 (9.7) 30 (8.5)
2 21 (11.9) 16 (9.1) 37 (10.5)
3 10 (5.7) 8 (4.5) 18 (5.1)
4 1 (0.6) 1 (0.6) 2 (0.6)
Missing/not known 6 (3.4) 1 (0.6) 7 (2.0)
NYHA classification, n (%)
I 31 (17.6) 30 (17.0) 61 (17.3)
II 74 (42.0) 68 (38.6) 142 (40.3)
III 59 (33.5) 71 (40.3) 130 (36.9)
IV 10 (5.7) 6 (3.4) 16 (4.5)
Missing/not known 2 (1.1) 1 (0.6) 3 (0.9)
CCS: Canadian Cardiac Society; NYHA: New York Heart Association; SD:
standard deviation.
Table 2: Cardiovascular status at the baseline of patients
randomized in the Amaze trial
Ablation Control Total
(n = 176) (n = 176) (n = 352)
Left ventricular function, n (%)
Poor (LVEF <30%) 4 (2.3) 8 (4.5) 12 (3.4)
Moderate (LVEF 30–50%) 50 (28.4) 56 (31.8) 106 (30.1)
Good (LVEF >50%) 122 (69.3) 112 (63.6) 234 (66.5)
Previous PCI, n (%) 16 (9.1) 14 (8.0) 30 (8.5)
Congestive cardiac failure, n (%) 5 (2.8) 1 (0.6) 6 (1.7)
Diabetes, n (%)
Insulin dependent 5 (2.8) 7 (4.0) 12 (3.4)
Non-insulin dependent 27 (15.3) 17 (9.7) 44 (12.5)
Hyperlipidaemia, n (%) 70 (39.8) 63 (35.8) 133 (37.8)
Atrial fibrillation class, n (%)
Paroxysmal 44 (25.0) 48 (27.3) 92 (26.1)
Persistent 30 (17.0) 19 (10.8) 49 (13.9)
Permanent 102 (58.0) 109 (61.9) 211 (59.9)
Atrial fibrillation history (months), n (%)
0–3 4 (2.3) 2 (1.1) 6 (1.7)
3–6 25 (14.2) 25 (14.2) 50 (14.2)
6–12 31 (17.6) 23 (13.1) 54 (15.3)
>12 115 (65.3) 126 (71.6) 241 (68.5)
Not known 1 (0.6) 1 (0.3)
Permanent pacemaker, n (%) 7 (4.0) 8 (4.5) 15 (4.3)
Previous cardioversion, n (%) 24 (13.6) 23 (13.1) 47 (13.4)
Previous ablation, n (%) 3 (1.7) 1 (0.6) 4 (1.1)
Other arrhythmias, n (%) 2 (1.1) 2 (1.1) 4 (1.1)
Anticoagulants, n (%) 137 (77.8) 137 (77.3) 274 (77.6)
Antiarrhythmics, n (%) 145 (82.4) 148 (84.1) 293 (83.2)
Actual procedure category, n (%)
MVR 39 (22.2) 48 (27.3) 87 (24.7)
CABG 35 (19.9) 34 (19.3) 69 (19.6)
AVR 32 (18.2) 23 (13.1) 55 (15.6)
CABG + AVR 16 (9.1) 21 (11.9) 37 (10.5)
CABG + MVR 14 (8.0) 13 (7.4) 27 (7.7)
All others 40 (22.7) 37 (21.0) 77 (21.9)
AVR: aortic valve replacement; CABG: coronary artery bypass grafting;
LVEF: left ventricular ejection fraction; MVR: mitral valve repair or replace-
ment; PCI: percutaneous coronary intervention.
Figure 2: Percentage of patients in SR and free from atrial fibrillation at 1 year
and 2 years after randomization. SR: sinus rhythm.
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for 141 (80%) ablation and 145 (82%) control patients, and 2-
year QALYs were known for 160 patients in each arm (91%).
Loss-to-follow-up reasons were similar for the 2 groups
(Fig. 1), which were also similar in demographics, symptomatic
status, cardiovascular profile and operations performed
(Tables 1 and 2). The left atrial (LA) appendage was resected or
excluded in 97 (55.1%) ablation arm patients and in 53 (30.1%)
control patients.
Primary outcome: sinus rhythm at 1 year
Among cases with complete ECG data, 87 of 141 (61.7%) ablation
patients were in SR at 1 year vs 68 of 145 (46.9%) controls (Fig. 2).
In the intention-to-treat analysis, the odds ratio (OR) (95% CI) for
1-year SR restoration in the ablation arm was 2.06 (1.20–3.54),
P = 0.0091. This increased from 1.6 (0.6–4.0) for the first 120
randomized patients to 2.9 (0.9–9.6) for the final 71 patients
randomized in the last 18 months. This suggests a learning curve,
but this was not proved by the probability analysis (Supplementary
Material, Fig. S1).
Primary outcome: quality-adjusted life years
The unadjusted, undiscounted mean (95% CI) QALY over 2 years was
1.489 (1.416–1.558) for the ablation arm and 1.485 (1.403–1.559) in
the control arm. In the intention-to-treat analysis, the adjusted mean
difference (95% CI) in QALYs at 2 years (ablation - control) was
-0.025 (-0.129 to 0.078, P= 0.6319).
Secondary outcomes
At 2 years, 69 of 118 (58.5%) ablation completers were in SR when
compared with 47 of 129 (36.4%) controls (Fig. 2). The adjusted
OR for SR at 2 years was 3.24 (95% CI 1.76–5.96). Significantly
fewer ablation patients received anticoagulants from 6 months
(Supplementary Material, Table S2) without a higher stroke rate:
13 strokes in 10 (5.7%) ablation patients and 19 in 16 (9.1%) con-
trol patients; the difference of -3.4% (95% CI -14.1–7.3%) was not
significant (the Fisher’s exact test P = 0.3083) nor was the difference
in stroke events between the 2 groups (log-linear model relative
rate 0.68 (95% CI 0.34–1.39, P = 0.292). Stroke-free survival was
similar in the 2 arms (HR = 0.99, 95% CI 0.64–1.53, P = 0.949,
Fig. 4). Fifteen (7 ablation and 8 control) patients already had per-
manent pacemakers at surgery. Ablation did not increase the need
for permanent pacemaker implantation after surgery (ablation 15
and control 17). Sixty (34.1%) ablation patients required 65 cardio-
versions and 67 (38.1%) control patients required 72 cardiover-
sions. Immediate cardioversion success rates were similar [48/65
(73.8%) ablation and 54/72 (75.0%) control]. There was no signifi-
cant difference in antiarrhythmic drug use throughout follow-up
(Supplementary Material, Table S2). There were no significant
Figure 3: Six-year cumulative mortality rate after patient randomization in the Amaze trial. ‘Maze’ refers to all atrial fibrillation ablation surgeries. CI: confidence inter-
val; HR: hazard ratio.
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differences between the 2 arms in any of the following outcomes
at any time point: NYHA, EQ-5D-3l and SF-36.
Safety
The mean (SD) cross-clamp time was longer by 5.1 min in the
ablation group [82.2 (37.2) vs 77.2 (48.6)], and bypass time was
longer by 18.9 min [118.1 (43.4) vs 99.3 (41.8)]. There were 5
(2.8%) operative deaths in the ablation group and 9 (5.1%)
among controls (P = 0.414). Over the trial course, there were 30
ablation and 25 control deaths (HR 1.23, 95% CI 0.73–2.10;
P = 0.437), so that adding AF surgery did not significantly affect
early or late mortality (Fig. 3).
There were 330 adverse events in 100 AF surgery patients and
333 in 111 controls (each 60%). Of them, 71 (42.5%) ablation and
84 (45.5%) control patients had at least 1 moderately severe
event, and 31 (18.6%) ablation and 38 (20.5%) control patients
had a severe event. Few events were ‘possibly related’ to treat-
ment: 23 in 17 (10.2%) ablation patients and 28 in 19 (10.3%)
control patients; 1 patient admitted to hospital for atrial flutter
(classed as ‘definitely related’ to treatment) was subsequently
found to be in the control group.
Subgroup analysis
Preplanned subgroup analysis showed no significant interaction
between 1-year SR restoration and type of AF (paroxysmal or
non-paroxysmal) or planned cardiac procedure (Fig. 5). The ran-
dom intercepts analysis showed that SR restoration rates varied
by surgeon across both arms, with an intraclass correlation
coefficient of 0.089. In the ablation arm, the highest odds for
1-year SR restoration occurred with a comprehensive LA lesion
set including the mitral isthmus lesion. Adding right atrial (RA)
lesions conveyed no further increase in SR restoration odds (to
be interpreted cautiously because of confounding associations
between lesion sets and surgeons). Post hoc analysis of the LA
appendage excision showed a significant interaction and was in-
creasingly used as the trial progressed for the ablation group but
not for controls.
Cost-effectiveness
Higher ablation costs resulted from the ablation device, length of
stay in critical care and readmissions (Table 3). The adjusted
mean incremental maze cost was £3533 (95% CI £1321–£5746),
significantly higher than control (P < 0.01). The adjusted mean
QALY difference was not significant (-0022, 95% CI -01231 to
00791; P = 0.67, Supplementary Material, Table S3). No analyses
suggested that ablation was cost-effective at 2 years at £30 000
per QALY. The smallest incremental cost-effectiveness ratio was
£53 538/QALY from an unplanned analysis limited to patients
randomized in the 2nd half of the trial (Supplementary Material,
Figs S2–S5).
Figure 4: Six-year cumulative mortality rate or stroke rate after patient randomization in the Amaze trial. ‘Maze’ refers to all atrial fibrillation ablation surgeries. CI: con-
fidence interval; HR: hazard ratio.
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DISCUSSION
In this pragmatic, multicentre trial, 1-year and 2-year SR restor-
ation rates were significantly higher for ablation patients than
controls and slightly higher than reported in a recent RCT meta-
analysis [15]. SR restoration rate in the control group was higher
than any previously reported through cardiac surgery alone [16,
17]. Control patients received the same postoperative care as trial
patients including postoperative cardioversion suggesting that,
with a determined effort, cardiac surgery alone can restore SR in
one-third of patients at 2 years, an outcome worth pursuing in
the absence of adjunct AF surgery.
The optimal lesion set remains controversial. The full Cox-
maze lesion set is established [18], and if there is a ‘dose–
response’ relationship, SR restoration rates should be better with
a more complete lesion. One RCT of AF surgery in mitral patients
found no significant difference in SR restoration between the
complete lesion set and pulmonary vein isolation alone [16], al-
though it was probably insufficiently powered to detect such a
difference. Many surgeons carry out only parts of the full
Cox-maze, and there is a wide range of lesion sets used.
Terminology is unhelpful with such procedures variously
described as maze, mini-maze, the LA maze or simply AF
ablation. The Amaze trial showed higher SR restoration rates with
a complete LA lesion set including the mitral annulus or ‘isthmus’
lesion but did demonstrate the benefit of adding RA lesions, al-
though the power to detect these differences was low and adding
such lesions has little impact on operative time or complexity
above a full LA lesion set.
We found no impact in QoL at 2 years, but this is relatively short
follow-up, and cardiac surgery alone achieves such an increase in
QoL [19] that it may be difficult to discern additional benefits from
AF surgery at this stage. Two factors may modify this conclusion in
future: there was significantly less anticoagulation in ablation pa-
tients postoperatively with no increase in stroke rate, and the
HESTER study [20] showed LA contractile recovery in most but not
all patients when ablation restores SR. These results lend support
to anticoagulation withdrawal when SR is restored after AF surgery,
but the varying extent of the LA contractile recovery suggests that
the LA function should be measured before contemplating with-
drawal. A continued follow-up of the Amaze patients will establish
whether QoL and survival advantages accrue over time.
The per-patient cost over 2 years was higher in the ablation
arm with no significant impact on discounted QALYs.
Deterministic and probabilistic sensitivity analyses confirmed this
and the probability that AF surgery would be cost-effective at
Figure 5: Forest plot showing the odds ratio of SR restoration at 1 year after randomization for predefined subgroups in the Amaze trial. Lesion set groupings are pro-
vided below [the left atrium, right atrium and pulmonary vein (PV)]. ‘Maze’ refers to all AF ablation surgeries. (i) Minimal left atrial (LA) lesion set: PV isolation only ± the
LA appendage line, (ii) more extensive LA-only lesion set excluding the mitral annulus, (iii) more extensive LA-only lesion set including the mitral annulus, (iv) minimal
LA lesion set and the right atrial (RA) lesion set, (v) more extensive LA lesion set excluding the mitral annulus + the RA lesion set and (vi) more extensive LA lesion set
including the mitral annulus + the RA lesion set. AF: atrial fibrillation; AVR: aortic valve replacement; CABG: coronary artery bypass grafting; CI: confidence interval;
MVR: mitral valve repair or replacement; RF: radiofrequency; SR: sinus rhythm.
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2 years was less than 5%, and alternative assumptions do not alter
this conclusion.
Strengths and limitations
The Amaze trial is the largest randomized trial to date to evaluate
adjunct AF surgery. It is unique in including all cardiac (not only
mitral) procedures, in having both patients and outcome asses-
sors blinded to treatment arm and in incorporating survival,
stroke-free survival and QoL as outcome measures. The prag-
matic design evaluated AF surgery as currently performed in clin-
ical practice, rather than what may be achievable in specialist
centres. The number of participating units and surgeons, the var-
iety of ablation devices and lesion sets and the interaction be-
tween these variables have improved result generalizability but
reduced the power to draw firm conclusions about the optimal
device and lesion set.
Recruitment is a widespread RCT problem. Logistic delays,
activity overestimation and rising awareness of AF surgery
among patients and clinicians affected recruitment rate. This
led to early stoppage of the trial at 88% recruitment when no
further funding was available, but the lower-than-expected loss
to follow-up reduced any impact on the trial power. Infrequent
follow-up (6, 12 and 24 months) is associated with under-
reporting of frequent events, illness severity and intensive ser-
vice use, but there is no recommended interval between
follow-ups [21, 22]. In the Amaze trial, 95% of the difference in
follow-up costs is related to readmissions (infrequent major
events), making cost underestimation unlikely. The cost-
effectiveness analysis was limited to 2 years and may not reflect
long-term benefits.
CONCLUSION
Adjunct AF surgery can be practised safely in a routine cardiac
surgical setting and increases SR restoration up to 2 years after
surgery. This electrophysiological success did not translate into
better 2-year survival or QoL, and the procedure is, therefore,
not proved to be cost-effective at 2 years. A longer follow-up will
determine whether AF surgery has an impact on these outcomes.
SUPPLEMENTARY MATERIAL
Supplementary material is available at EJCTS online.
ACKNOWLEDGEMENTS
We acknowledge the work of Fay Cafferty, Mark Schulpher and
Derek Todd who formed the data monitoring committee chaired
by James Roxburgh. We thank Brian Elliott and Paul Kinnersley who
participated in the Trial Steering Committee chaired by Dai
Rowlands. We thank surgeons Haitham Abunasra, Simon Allen,
Benjamin Bridgewater, Pedro Catarino, Stephen Clarke, John Dark,
John Dunning, Leonidas Hadjinikolao, Jonathan Hyde, David
Jenkins, Anthony de Souza, Stephen Large, Michael Lewis, Neil
Moat, Narain Moorjani Suku Nair, Choo Ng, Rajesh Patel, Jacek
Szostek, Augustine Tang, Graham Venn, John Wallwork and Nizar
Yonan who also recruited to the trial. The Papworth Trials Unit staff
supported the design, recruitment, co-ordination, conduct, data
management, analysis and quality assurance. We also thank Hester
Goddard for the trial set-up and grant application, and Donna
Alexander for continuous support throughout.
Funding
This work was supported by the NIHR Health Technology
Assessment programme.
Conflict of interest: Amaze operations used a multitude of devi-
ces, including Atricure products (although this is not specified in
the manuscript and no specific products are mentioned any-
where). SAMN and YAO have received expenses and lecture fees
from Atricure for participating in educational courses on atrial
fibrillation.
Table 3: Mean (SD) of per-patient costs of resource use with imputation
Ablation (n = 176) Control (n = 176) Difference (ablation - control)
Mean cost/patient SD Mean cost/patient SD
Health service use
Primary admission
Theatre use £5225 £1594 £4949 £1863 £276
Ablation device £1212 £408 £14 £133 £1197
Adult critical care £4029 £7600 £3065 £5586 £964
Cardiac ward £3397 £4661 £3064 £2014 £333
Rehabilitation £48 £325 £148 £1082 -£100
Acute trust £937 £6105 £165 £1409 £772
Subtotal £14 847 £12 474 £11 404 £7194 £3 443
Medication (whole trial period) £618 £1584 £681 £2765 -£63
Follow-up
Readmissions £1650 £4192 £1220 £2994 £430
Tests £388 £376 £344 £283 £44
Healthcare visits £1179 £1061 £1193 £1052 -£14
Subtotal £3217 £5629 £2757 £4329 £460
Grand total £18 681 £13 340 £14 842 £8295 £3839
SD: standard deviation.
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